These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19755144)

  • 1. Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate.
    Esen M; Kremsner PG; Schleucher R; Gässler M; Imoukhuede EB; Imbault N; Leroy O; Jepsen S; Knudsen BW; Schumm M; Knobloch J; Theisen M; Mordmüller B
    Vaccine; 2009 Nov; 27(49):6862-8. PubMed ID: 19755144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon.
    Mordmüller B; Szywon K; Greutelaers B; Esen M; Mewono L; Treut C; Mürbeth RE; Chilengi R; Noor R; Kilama WL; Imoukhuede EB; Imbault N; Leroy O; Theisen M; Jepsen S; Milligan P; Fendel R; Kremsner PG; Issifou S
    Vaccine; 2010 Sep; 28(41):6698-703. PubMed ID: 20696154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children.
    Bélard S; Issifou S; Hounkpatin AB; Schaumburg F; Ngoa UA; Esen M; Fendel R; de Salazar PM; Mürbeth RE; Milligan P; Imbault N; Imoukhuede EB; Theisen M; Jepsen S; Noor RA; Okech B; Kremsner PG; Mordmüller B
    PLoS One; 2011; 6(7):e22525. PubMed ID: 21829466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
    Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
    Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral immune response to Plasmodium falciparum vaccine candidate GMZ2 and its components in populations naturally exposed to seasonal malaria in Ethiopia.
    Mamo H; Esen M; Ajua A; Theisen M; Mordmüller B; Petros B
    Malar J; 2013 Feb; 12():51. PubMed ID: 23383869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children.
    Sirima SB; Mordmüller B; Milligan P; Ngoa UA; Kironde F; Atuguba F; Tiono AB; Issifou S; Kaddumukasa M; Bangre O; Flach C; Christiansen M; Bang P; Chilengi R; Jepsen S; Kremsner PG; Theisen M;
    Vaccine; 2016 Aug; 34(38):4536-4542. PubMed ID: 27477844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens.
    Amoani B; Gyan B; Sakyi SA; Abu EK; Nuvor SV; Barnes P; Sarkodie-Addo T; Ahenkorah B; Sewor C; Dwomoh D; Theisen M; Cappello M; Wilson MD; Adu B
    BMC Infect Dis; 2021 Apr; 21(1):332. PubMed ID: 33832450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas.
    Jepsen MP; Jogdand PS; Singh SK; Esen M; Christiansen M; Issifou S; Hounkpatin AB; Ateba-Ngoa U; Kremsner PG; Dziegiel MH; Olesen-Larsen S; Jepsen S; Mordmüller B; Theisen M
    J Infect Dis; 2013 Aug; 208(3):479-88. PubMed ID: 23624363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.
    Mistarz UH; Singh SK; Nguyen TTTN; Roeffen W; Yang F; Lissau C; Madsen SM; Vrang A; Tiendrebeogo RW; Kana IH; Sauerwein RW; Theisen M; Rand KD
    Pharm Res; 2017 Sep; 34(9):1970-1983. PubMed ID: 28646324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.
    Dejon-Agobe JC; Ateba-Ngoa U; Lalremruata A; Homoet A; Engelhorn J; Nouatin OP; Edoa JR; Fernandes JF; Esen M; Mouwenda YD; Betouke Ongwe EM; Massinga-Loembe M; Hoffman SL; Sim BKL; Theisen M; Kremsner PG; Adegnika AA; Lell B; Mordmüller B
    Clin Infect Dis; 2019 Sep; 69(8):1377-1384. PubMed ID: 30561539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas.
    Baptista BO; de Souza ABL; Riccio EKP; Bianco-Junior C; Totino PRR; Martins da Silva JH; Theisen M; Singh SK; Amoah LE; Ribeiro-Alves M; Souza RM; Lima-Junior JC; Daniel-Ribeiro CT; Pratt-Riccio LR
    Malar J; 2022 Jan; 21(1):6. PubMed ID: 34983540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
    Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The GMZ2 malaria vaccine: from concept to efficacy in humans.
    Theisen M; Adu B; Mordmüller B; Singh S
    Expert Rev Vaccines; 2017 Sep; 16(9):907-917. PubMed ID: 28699823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
    Stoute JA; Slaoui M; Heppner DG; Momin P; Kester KE; Desmons P; Wellde BT; Garçon N; Krzych U; Marchand M
    N Engl J Med; 1997 Jan; 336(2):86-91. PubMed ID: 8988885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen.
    Baldwin SL; Roeffen W; Singh SK; Tiendrebeogo RW; Christiansen M; Beebe E; Carter D; Fox CB; Howard RF; Reed SG; Sauerwein R; Theisen M
    Vaccine; 2016 Apr; 34(19):2207-15. PubMed ID: 26994314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months.
    Lusingu JP; Gesase S; Msham S; Francis F; Lemnge M; Seth M; Sembuche S; Rutta A; Minja D; Segeja MD; Bosomprah S; Cousens S; Noor R; Chilengi R; Druilhe P
    Malar J; 2009 Jul; 8():163. PubMed ID: 19607731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa.
    Sirima SB; Nébié I; Ouédraogo A; Tiono AB; Konaté AT; Gansané A; Dermé AI; Diarra A; Ouédraogo A; Soulama I; Cuzzin-Ouattara N; Cousens S; Leroy O
    Vaccine; 2007 Mar; 25(14):2723-32. PubMed ID: 17280744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants.
    Carvalho LJ; Alves FA; Bianco C; Oliveira SG; Zanini GM; Soe S; Druilhe P; Theisen M; Muniz JA; Daniel-Ribeiro CT
    Clin Diagn Lab Immunol; 2005 Feb; 12(2):242-8. PubMed ID: 15699417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
    Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J;
    Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturally acquired immune responses to malaria vaccine candidate antigens MSP3 and GLURP in Guahibo and Piaroa indigenous communities of the Venezuelan Amazon.
    Baumann A; Magris MM; Urbaez ML; Vivas-Martinez S; Durán R; Nieves T; Esen M; Mordmüller BG; Theisen M; Avilan L; Metzger WG
    Malar J; 2012 Feb; 11():46. PubMed ID: 22335967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.